Symbols / AZTR $0.16 -2.22%
AZTR Chart
About
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.52M |
| Enterprise Value | 975.55K | Income | -10.96M | Sales | — |
| Book/sh | 0.35 | Cash/sh | 0.13 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.30 | PEG | — |
| P/S | — | P/B | 0.45 | P/C | — |
| EV/EBITDA | -0.09 | EV/Sales | — | Quick Ratio | 2.07 |
| Current Ratio | 2.83 | Debt/Eq | 11.10 | LT Debt/Eq | — |
| EPS (ttm) | -2.25 | EPS next Y | -0.52 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-27 17:00 | ROA | -110.69% |
| ROE | -230.65% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 15.89M |
| Shs Float | 16.18M | Short Float | 1.15% | Short Ratio | 0.07 |
| Short Interest | — | 52W High | 2.67 | 52W Low | 0.15 |
| Beta | -1.50 | Avg Volume | 1.48M | Volume | 216.06K |
| Target Price | $1.35 | Recom | Buy | Prev Close | $0.16 |
| Price | $0.16 | Change | -2.22% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$1.35
Mean price target
2. Current target
$0.16
Latest analyst target
3. DCF / Fair value
$-7.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.16
Low
$1.00
High
$1.70
Mean
$1.35
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-24 | main | Maxim Group | Buy → Buy | $4 |
- Biotech Azitra warned on NYSE listing, auditor raises going-concern doubt - Stock Titan Fri, 13 Mar 2026 21
- Azitra, Inc. Announces Reverse Stock Split - PR Newswire Mon, 11 Aug 2025 07
- Azitra Faces NYSE American Noncompliance and Delisting Risk - TipRanks Fri, 13 Mar 2026 21
- Biotech Azitra backs rash and rare-skin trials, awaits 2026 data - Stock Titan Fri, 27 Feb 2026 08
- AZTR: New Site for ATR-04 Trial - Yahoo Finance Wed, 04 Mar 2026 08
- Azitra receives NYSE delisting warning over equity shortfall - Investing.com Fri, 13 Mar 2026 21
- Azitra receives notice of non-compliance with NYSE American listing standards - MSN Fri, 13 Mar 2026 23
- Biotech Azitra scraps plans for March 6 special stockholder meeting - Stock Titan hu, 05 Mar 2026 08
- Azitra stock soars after positive preclinical data for ichthyosis treatment - Investing.com Mon, 20 Oct 2025 07
- Azitra Cancels Special Stockholder Meeting and Proposals - TipRanks hu, 05 Mar 2026 08
- Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders - Finviz hu, 05 Mar 2026 08
- Azitra (NYSE American: AZTR) widens 2025 loss while pushing key skin programs - Stock Titan Fri, 27 Feb 2026 08
- Shareholder vote stalls at Azitra with only 13% of stock voting - Stock Titan Fri, 06 Feb 2026 08
- MD Anderson joins test of skin therapy to keep cancer patients on EGFR drugs - Stock Titan ue, 24 Feb 2026 08
- $20M Strategic Investment Accelerates Azitra's Breakthrough Treatments for 150,000 Rare Disease Patients - Stock Titan hu, 24 Apr 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 47600 | 10034 | — | Purchase at price 0.21 per share. | STASKEY NORM | Chief Financial Officer | — | 2024-03-28 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 80.01 | 847.16K | 7.34K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -10.49M | -12.53M | -10.71M | -10.02M |
| TotalUnusualItems | 381.00 | 4.03M | 34.93K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 381.00 | 4.03M | 34.93K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.96M | -8.97M | -11.28M | -10.68M |
| ReconciledDepreciation | 453.14K | 448.24K | 425.55K | 405.98K |
| EBITDA | -10.49M | -8.50M | -10.67M | -10.02M |
| EBIT | -10.94M | -8.95M | -11.10M | -10.43M |
| NetInterestIncome | 62.62K | 110.39K | -166.15K | -247.07K |
| InterestExpense | 7.59K | 12.16K | 167.73K | 251.89K |
| InterestIncome | 70.21K | 122.55K | 1.58K | 4.82K |
| NormalizedIncome | -10.96M | -12.15M | -11.31M | -10.68M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.96M | -8.97M | -11.28M | -10.68M |
| TotalExpenses | 10.97M | 10.99M | 8.14M | 9.74M |
| TotalOperatingIncomeAsReported | -10.97M | -10.99M | -7.45M | -9.45M |
| DilutedAverageShares | 571.16K | 34.51K | 60.49K | 60.49K |
| BasicAverageShares | 571.16K | 34.51K | 60.49K | 60.49K |
| DilutedEPS | -15.70 | -366.17 | -222.33 | -193.55 |
| BasicEPS | -15.70 | -366.17 | -222.33 | -193.55 |
| DilutedNIAvailtoComStockholders | -10.96M | -8.97M | -12.64M | -13.45M |
| NetIncomeCommonStockholders | -10.96M | -8.97M | -12.64M | -13.45M |
| PreferredStockDividends | 1.36M | 2.77M | 2.77M | |
| NetIncome | -10.96M | -8.97M | -11.28M | -10.68M |
| NetIncomeIncludingNoncontrollingInterests | -10.96M | -8.97M | -11.28M | -10.68M |
| NetIncomeContinuousOperations | -10.96M | -8.97M | -11.28M | -10.68M |
| TaxProvision | 8.32K | 9.03K | 17.31K | 0.00 |
| PretaxIncome | -10.95M | -8.96M | -11.27M | -10.68M |
| OtherIncomeExpense | -43.01K | 1.92M | -3.65M | -979.69K |
| OtherNonOperatingIncomeExpenses | -43.39K | -2.12M | -3.68M | -979.69K |
| SpecialIncomeCharges | 0.00 | 232.51K | ||
| OtherSpecialCharges | -232.51K | |||
| GainOnSaleOfSecurity | 381.00 | 4.03M | 34.93K | |
| NetNonOperatingInterestIncomeExpense | 62.62K | 110.39K | -166.15K | -247.07K |
| InterestExpenseNonOperating | 7.59K | 12.16K | 167.73K | 251.89K |
| InterestIncomeNonOperating | 70.21K | 122.55K | 1.58K | 4.82K |
| OperatingIncome | -10.97M | -10.99M | -7.45M | -9.45M |
| OperatingExpense | 10.97M | 10.99M | 8.14M | 9.74M |
| ResearchAndDevelopment | 4.84M | 4.72M | 3.64M | 6.10M |
| SellingGeneralAndAdministration | 6.13M | 6.27M | 4.49M | 3.64M |
| GeneralAndAdministrativeExpense | 6.13M | 6.27M | 4.49M | 3.64M |
| OtherGandA | 6.13M | 6.27M | 4.49M | 3.64M |
| TotalRevenue | 0.00 | 7.50K | 686.00K | 284.00K |
| OperatingRevenue | 0.00 | 7.50K | 686.00K | 284.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 10.74M | 1.15M | 60.55K | 60.49K |
| ShareIssued | 10.74M | 1.15M | 60.55K | 60.49K |
| NetDebt | 3.11M | |||
| TotalDebt | 422.08K | 555.51K | 885.95K | 7.73M |
| TangibleBookValue | 3.48M | 5.45M | 2.70M | -36.48M |
| InvestedCapital | 3.80M | 5.70M | 2.91M | -29.66M |
| WorkingCapital | 1.95M | 3.85M | 932.38K | 1.91M |
| NetTangibleAssets | 3.48M | 5.45M | 2.70M | -36.48M |
| CapitalLeaseObligations | 422.08K | 555.51K | 885.95K | 1.13M |
| CommonStockEquity | 3.80M | 5.70M | 2.91M | -36.26M |
| TotalCapitalization | 3.80M | 5.70M | 2.91M | -29.66M |
| TotalEquityGrossMinorityInterest | 3.80M | 5.70M | 2.91M | -36.26M |
| StockholdersEquity | 3.80M | 5.70M | 2.91M | -36.26M |
| RetainedEarnings | -68.52M | -57.57M | -48.60M | -37.31M |
| AdditionalPaidInCapital | 72.32M | 63.26M | 51.51M | 1.05M |
| CapitalStock | 1.07K | 114.00 | 40.00 | 104.00 |
| CommonStock | 1.07K | 114.00 | 40.00 | 104.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 1.22M | 1.66M | 2.20M | 43.43M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 156.19K | 284.65K | 599.14K | 41.21M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 33.69M | 33.69M | |
| DerivativeProductLiabilities | 0.00 | 381.00 | 35.45K | 70.28K |
| LongTermDebtAndCapitalLeaseObligation | 156.19K | 284.27K | 563.69K | 7.44M |
| LongTermCapitalLeaseObligation | 156.19K | 284.27K | 563.69K | 840.90K |
| LongTermDebt | 6.60M | 992.02K | ||
| CurrentLiabilities | 1.07M | 1.38M | 1.60M | 2.22M |
| OtherCurrentLiabilities | 198.98K | |||
| CurrentDeferredLiabilities | 0.00 | 156.00K | 15.00K | |
| CurrentDeferredRevenue | 0.00 | 156.00K | 15.00K | |
| CurrentDebtAndCapitalLeaseObligation | 265.89K | 271.24K | 322.25K | 287.38K |
| CurrentCapitalLeaseObligation | 265.89K | 271.24K | 322.25K | 287.38K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 37.88K | 32.97K | 31.07K | 27.08K |
| PayablesAndAccruedExpenses | 565.22K | 1.07M | 1.25M | 1.75M |
| CurrentAccruedExpenses | 159.60K | 569.82K | 352.59K | 966.88K |
| InterestPayable | 0.00 | 223.79K | 59.18K | |
| Payables | 405.61K | 501.83K | 897.27K | 784.69K |
| TotalTaxPayable | 6.26K | 11.57K | 0.00 | 0.00 |
| IncomeTaxPayable | 6.26K | 11.57K | 0.00 | 0.00 |
| AccountsPayable | 399.36K | 490.25K | 897.27K | 784.69K |
| TotalAssets | 5.03M | 7.36M | 5.12M | 7.17M |
| TotalNonCurrentAssets | 2.01M | 2.13M | 2.58M | 3.03M |
| OtherNonCurrentAssets | 47.40K | 46.94K | 47.76K | 47.51K |
| NonCurrentDeferredAssets | 679.91K | 631.28K | 742.23K | 800.83K |
| GoodwillAndOtherIntangibleAssets | 316.67K | 246.42K | 210.88K | 219.57K |
| OtherIntangibleAssets | 316.67K | 246.42K | 210.88K | 219.57K |
| NetPPE | 962.08K | 1.21M | 1.58M | 1.96M |
| AccumulatedDepreciation | -633.04K | -515.00K | -401.99K | -286.55K |
| GrossPPE | 1.60M | 1.72M | 1.98M | 2.25M |
| Leases | 28.86K | 28.86K | 28.86K | 28.86K |
| OtherProperties | 1.50M | 1.62M | 1.88M | 2.15M |
| MachineryFurnitureEquipment | 50.99K | 55.14K | 55.14K | 55.14K |
| BuildingsAndImprovements | 14.93K | 14.93K | 14.93K | 14.93K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.02M | 5.23M | 2.54M | 4.14M |
| CurrentDeferredAssets | 0.00 | 4.11K | 67.86K | 216.89K |
| PrepaidAssets | 809.95K | 567.57K | 448.26K | 160.13K |
| Receivables | 141.29K | 101.90K | 223.47K | 266.21K |
| TaxesReceivable | 140.38K | 101.66K | 125.22K | 83.39K |
| AccountsReceivable | 912.00 | 233.00 | 98.25K | 182.82K |
| CashCashEquivalentsAndShortTermInvestments | 2.07M | 4.55M | 1.80M | 3.49M |
| CashAndCashEquivalents | 2.07M | 4.55M | 1.80M | 3.49M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.41M | -10.56M | -7.68M | -8.69M |
| RepaymentOfDebt | -16.06K | -14.60K | -7.39K | 0.00 |
| IssuanceOfDebt | 0.00 | 4.35M | 984.39K | |
| IssuanceOfCapitalStock | 9.03M | 13.35M | 5.99M | 0.00 |
| CapitalExpenditure | -186.06K | -379.25K | -318.26K | -341.01K |
| EndCashPosition | 2.07M | 4.55M | 1.80M | 3.49M |
| BeginningCashPosition | 4.55M | 1.80M | 3.49M | 8.04M |
| ChangesInCash | -2.49M | 2.76M | -1.70M | -4.55M |
| FinancingCashFlow | 8.92M | 13.32M | 5.98M | 4.13M |
| CashFlowFromContinuingFinancingActivities | 8.92M | 13.32M | 5.98M | 4.13M |
| NetOtherFinancingCharges | -96.86K | -37.48K | -216.89K | |
| ProceedsFromStockOptionExercised | 0.00 | 19.10K | 0.00 | 1.51K |
| NetCommonStockIssuance | 9.03M | 13.35M | 5.99M | 0.00 |
| CommonStockIssuance | 9.03M | 13.35M | 5.99M | 0.00 |
| NetIssuancePaymentsOfDebt | -16.06K | -14.60K | -7.39K | 4.35M |
| NetLongTermDebtIssuance | -16.06K | -14.60K | -7.39K | 4.35M |
| LongTermDebtPayments | -16.06K | -14.60K | -7.39K | 0.00 |
| LongTermDebtIssuance | 0.00 | 4.35M | 984.39K | |
| InvestingCashFlow | -182.91K | -379.25K | -318.26K | -336.76K |
| CashFlowFromContinuingInvestingActivities | -182.91K | -379.25K | -318.26K | -336.76K |
| NetOtherInvestingChanges | -180.80K | -196.27K | ||
| NetIntangiblesPurchaseAndSale | -127.11K | -9.87K | ||
| PurchaseOfIntangibles | -127.11K | -9.87K | ||
| NetPPEPurchaseAndSale | -21.06K | -8.57K | -26.54K | -28.85K |
| SaleOfPPE | 3.15K | 0.00 | 0.00 | 4.25K |
| PurchaseOfPPE | -24.21K | -8.57K | -26.54K | -33.10K |
| CapitalExpenditureReported | -161.85K | -370.68K | -291.71K | -307.91K |
| OperatingCashFlow | -11.22M | -10.18M | -7.36M | -8.35M |
| CashFlowFromContinuingOperatingActivities | -11.22M | -10.18M | -7.36M | -8.35M |
| ChangeInWorkingCapital | -797.23K | -441.72K | -753.43K | 310.76K |
| ChangeInOtherWorkingCapital | -5.32K | 18.41K | -156.00K | 141.00K |
| ChangeInOtherCurrentLiabilities | -304.91K | -315.84K | -283.10K | -268.51K |
| ChangeInOtherCurrentAssets | -461.00 | 819.00 | -253.00 | 694.00 |
| ChangeInPayablesAndAccruedExpense | -500.32K | -140.53K | -68.68K | 420.75K |
| ChangeInPayable | -140.53K | -68.68K | 420.75K | 274.14K |
| ChangeInAccountPayable | -140.53K | -68.68K | 420.75K | 282.98K |
| ChangeInTaxPayable | 0.00 | -8.83K | ||
| ChangeInIncomeTaxPayable | 0.00 | -8.83K | ||
| ChangeInPrepaidAssets | 53.18K | -119.31K | -288.12K | -49.84K |
| ChangeInReceivables | -39.40K | 114.74K | 42.73K | 66.67K |
| ChangesInAccountReceivables | -679.00 | 98.02K | 84.56K | -21.95K |
| OtherNonCashItems | 10.90K | 2.13M | 3.80M | 1.42M |
| StockBasedCompensation | 62.74K | 245.05K | 151.50K | 184.47K |
| AssetImpairmentCharge | 0.00 | 442.79K | 351.36K | 0.00 |
| DepreciationAmortizationDepletion | 453.14K | 448.24K | 425.55K | 405.98K |
| DepreciationAndAmortization | 453.14K | 448.24K | 425.55K | 405.98K |
| AmortizationCashFlow | 13.71K | 11.16K | 7.64K | |
| AmortizationOfIntangibles | 13.71K | 11.16K | 7.64K | |
| Depreciation | 439.43K | 437.07K | 417.91K | 405.98K |
| OperatingGainsLosses | 1.69K | -4.04M | -49.70K | 7.10K |
| GainLossOnInvestmentSecurities | -381.00 | -4.03M | -34.83K | -821.00 |
| NetForeignCurrencyExchangeGainLoss | 0.00 | -14.20K | 0.00 | |
| GainLossOnSaleOfPPE | 2.07K | 4.86K | 41.42K | 7.92K |
| NetIncomeFromContinuingOperations | -10.96M | -8.97M | -11.28M | -10.68M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AZTR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|